{{Rsnum
|rsid=1870584
|Gene=MAP2K4
|Chromosome=17
|position=12144227
|Orientation=plus
|GMAF=0.4417
|Gene_s=MAP2K4
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 30.6 | 55.9 | 13.5
| HCB | 17.8 | 50.4 | 31.9
| JPT | 17.4 | 53.2 | 29.4
| YRI | 45.9 | 39.7 | 14.4
| ASW | 42.9 | 48.2 | 8.9
| CHB | 17.8 | 50.4 | 31.9
| CHD | 12.3 | 50.9 | 36.8
| GIH | 18.8 | 55.4 | 25.7
| LWK | 36.7 | 50.5 | 12.8
| MEX | 33.3 | 49.1 | 17.5
| MKK | 24.7 | 48.1 | 27.3
| TSI | 39.8 | 50.0 | 10.2
| HapMapRevision=28
}}{{PMID Auto GWAS
  |PMID=22952603
  |Trait=Response to amphetamines
  |Title=Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13).
  |RiskAllele=
  |Pval=5E-6
  |OR=NR
  |ORtxt=NR
  |OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}